Please note that masks are still required in all Blue Ridge Cancer Care offices regardless of vaccination status.
Learn more about this and other current Covid-19 policies.

Research Institute

Zanubrutinib in Patients w/previously treated B-Cell Lymphoma

A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib 

Disease Types: Lymphoma

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib 

For More Information:

https://clinicaltrials.gov/ct2/show/NCT04116437?term=A+Phase+2%2C+Multicenter%2C+Single-arm+Study+of+Zanubrutinib+%28BGB-3111%29+in+Patients+with+Previously+Treated+B-Cell+Lymphoma+Intolerant+of+Prior+Treatment+with+Ibrutinib+and%2For+Acalabrutinib&draw=2&rank=1